2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy
2014
Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity.
Yu J, Cramer L, Herrin J, Soulos P, Potosky A, Gross C. Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity. Journal Of Clinical Oncology 2014, 32: 89-89. DOI: 10.1200/jco.2014.32.4_suppl.89.Peer-Reviewed Original ResearchStereotactic body radiosurgeryGU complicationsProstate cancerSBRT patientsIMRT patientsGU toxicityRate of complicationsRetrospective observational studyBladder outlet obstructionHigh cure ratesRandom-effects modelCost of treatmentOutlet obstructionUrinary incontinenceTreatment initiationRetrospective studyCure rateUrethral strictureDiagnosis codesPrimary treatmentObservational studyRadiation therapyMean costMedicare beneficiariesPatients